4th Quarter - Report

BOSTON SCIENTIFIC CORPORATION for BOSTON SCIENTIFIC CORPORATION

Firm
Client
Income
—
Expenses
$480,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Financial Institutions/Investments/Securities FIN

H.R. 3795, to enact the Over-the-Counter Derivatives Markets Act of 2009, provisions related to changing the regulation on over-the-counter derivatives and how they are used by corporations H.R.4173, to provide for financial regulatory reform, to protect consumers and investors, to enhance Federal understanding of insurance issues, to regulate over-the-counter derivatives markets, and for other purposes with provisions specifically changing the regulation on over-the-counter derivatives and how they are used by corporations Senate draft legislation by Senator Dodd on financial reform with provisions on the regulation of over-the-counter derivatives

LobbyistCovered position, as disclosed
BRENDA BECKER —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC); Government Accountability Office (GAO); Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO); Office of Management & Budget (OMB)

Bills named: H.R. 3795 (111th), H.R. 4173 (111th)

Taxation/Internal Revenue Code TAX

Medical device tax as included as a means to pay for health care reform in H.R. 3962, the Affordable Health Care for America Act and the Senate Manager's Amendment (SA3298) on health care reform H.Con Res 85 and S.Con Res 13, the FY2010 budget resolution and provisions related to the taxation of foreign earnings of U.S. multinational corporations H.R. 4213, the Tax Extenders Act of 2009, specifically including a provision to extend the research and development tax credit S.1203, the GROWTH Act, a bill to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit

LobbyistCovered position, as disclosed
BRENDA BECKER —
JEAN CECIL FRICK —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —
SCOTT REID —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC); Congressional Budget Office (CBO); SENATE; Government Accountability Office (GAO)

Bills named: H.R. 3962 (111th), S.Con.Res. 13 (111th), H.R. 4213 (111th), H.Con.Res. 85 (111th), S. 1203 (111th)

Health Issues HCR

H.R. 3590, the Patient Protection and Affordable Care Act, the legislative vehicle used to pass Leader Reid's manager's amendment regarding health care reform on the Senate floor H.R. 3962, Affordable Health Care for America Act,to provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes Other Senate and House Committee Health Reform bills with an emphasis on physician disclosure, comparative effectiveness research, pain research, Medicare secondary payer, bundling, gainsharing, medical device registry, and medical device tax. Medicare Secondary Payer provision, which was included in Ways and Means Chairman's Mark for HR 3200, the America's Affordable Health Choices Act, that would have increased exposure to liability for suppliers S.540, Medical Device Safety Act, a bill that would remove federal preemption protection for certain medical devices H.R.1346, Medical Device Safety Act, a bill that would remove federal preemption protection for certain medical devices Reform of the 510 (k) regulatory pathway H.R. 759, Food and Drug Administration Globalization Act, a bill to improve the safety of food, drugs, devices, and cosmetics S. 882, the Drug and Device Accountability Act, a bill to ensure the safety and quality of medical products and enhance the authorities of the FDA H.R. 2502, Comparative Effectiveness Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and create a Comparative Effectiveness Research Trust Fund S.1213, Patient-Centered Outcomes Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and to establish a Patient-Centered Outcomes Research Trust Fund H.R. 2824, Doctor-Patient Relationship and Research Protection Act, a bill to support federally funded comparative effectiveness research for drugs, devices, and other therapies S.1142, Informed Health Care Decision Making Act, a bill with respect to the inclusion of effectiveness information in drug and device labeling and advertising H.R. 3090, Health Equity &Accountability Act of 2009, provides for the elimination of racial and ethnic health disparities S.660, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies H.R. 756, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies S.1390, the Defense Authorization Bill, provisions related to pain management which would require a comprehensive pain care policy on pain management by the military health care system

LobbyistCovered position, as disclosed
BRENDA BECKER —
JEAN CECIL FRICK —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —
SCOTT REID —

Contacted: Office of Management & Budget (OMB); Medicare Payment Advisory Commission (MedPAC); Congressional Budget Office (CBO); SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Government Accountability Office (GAO)

Bills named: S. 1390 (111th), H.R. 3090 (111th), H.R. 759 (111th), S. 660 (111th), H.R. 2502 (111th), H.R. 1346 (111th), S. 1213 (111th), H.R. 3590 (111th), S. 540 (111th), H.R. 3200 (111th), S. 882 (111th), H.R. 756 (111th), S. 1142 (111th), H.R. 3962 (111th), H.R. 2824 (111th)

Medicare/Medicaid MMM

S.660, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies H.R. 756, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies S.1380, Medicare Payment Advisory Commission (MedPAC) Reform Act, a bill to make the commission an executive branch agency, and provide the Commission new resources and authority to implement Medicare payment policy S.301, Physician Payments Sunshine Act, a bill that would require disclosure of the relationships between physicians and the manufacturers of drugs and devices H.R. 3138, Physician Payments Sunshine Act, a bill that would require disclosure of the relationships between physicians and the manufacturers of drugs and devices H.R. 2502, Comparative Effectiveness Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and create a Comparative Effectiveness Research Trust Fund S.1213, Patient-Centered Outcomes Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and to establish a Patient-Centered Outcomes Research Trust Fund H.R. 2824, Doctor-Patient Relationship and Research Protection Act, a bill to support federally funded comparative effectiveness research for drugs, devices, and other therapies S.1142, Informed Health Care Decision Making Act, a bill with respect to the inclusion of effectiveness information in drug and device labeling and advertising

LobbyistCovered position, as disclosed
BRENDA BECKER —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —
SCOTT REID —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 660 (111th), S. 1213 (111th), H.R. 3138 (111th), S. 1142 (111th), S. 1380 (111th), H.R. 2824 (111th), H.R. 2502 (111th), H.R. 756 (111th), S. 301 (111th)

Food Industry (safety, labeling, etc.) FOO

HR 2749, Food Safety Enhancement Act of 2009, grants FDA the authority and resources to oversee the safety of the nation's food supply. Includes provisions related to registration fees, device import safety fees, and unique identifier provisions.

LobbyistCovered position, as disclosed
BRENDA BECKER —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —

Contacted: HOUSE OF REPRESENTATIVES; Medicare Payment Advisory Commission (MedPAC); Congressional Budget Office (CBO); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE; Government Accountability Office (GAO); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 2749 (111th)

Labor Issues/Antitrust/Workplace LBR

S.560, the Employee Free Choice Act, a bill to establish an efficient system to enable employees to form, join, or assist labor organizations and to provide for mandatory injunctions for unfair labor practices during the organizing efforts H.R. 1409, the Employee Free Choice Act, a bill to establish an efficient system to enable employees to form, join, assist labor organizations, and to provide for mandatory injunctions for unfair labor practices during the organizing efforts

LobbyistCovered position, as disclosed
BRENDA BECKER —
JEAN CECIL FRICK —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —

Contacted: Medicare Payment Advisory Commission (MedPAC); SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Government Accountability Office (GAO); Congressional Budget Office (CBO); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 1409 (111th), S. 560 (111th)

Transportation TRA

H.R. 4016, the Hazardous Materials Transportation Safety Act of 2009, specifically regarding the transportation of lithium batteries

LobbyistCovered position, as disclosed
BRENDA BECKER —
JEAN CECIL FRICK —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —

Contacted: Congressional Budget Office (CBO); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); SENATE; Government Accountability Office (GAO)

Bills named: H.R. 4016 (111th)

Copyright/Patent/Trademark CPT

S.515. Patent Reform Act of 2009, provisions related specifically to innovative technologies H.R. 1260, Patent Reform Act of 2009, provisions related specifically to innovative technologies

LobbyistCovered position, as disclosed
BRENDA BECKER —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —

Contacted: Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); Office of Management & Budget (OMB)

Bills named: H.R. 1260 (111th), S. 515 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.